The FDA clearance of Hologic's Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is a significant milestone for the company. This approval allows Hologic to market and sell the test in the US, potentially increasing its revenues and market share in the molecular diagnostics sector. The test's ability to detect and differentiate four prevalent respiratory viruses makes it a valuable tool for healthcare professionals, which may lead to increased demand and a positive impact on Hologic's stock price in the short term.